Photon etc. has declared the introduction of IRIS, a newly-developed innovative device for an effective, non-invasive localization of biomolecules in the eye fundus. The company is focused on the hyperspectral retinal imaging field which is gradually advancing.
Photon etc. announces the launch of IRISTM, an innovative Retinal Hyperspectral Imaging system
IRIS is an efficiently-flexible instrument that uses a modified mydriatic retinal camera and the proprietary Tunable Laser Source to generate high definition retinal imaging with wavelength ranges measuring from 420 to 1000 nm. IRIS serves to be a perfect research tool ensuring precise comprehension and forecast of retinal diseases including macular degeneration with respect to age and diabetic retinopathy.
An automatic spectral calibration system has been specifically designed and upgraded for conducting ophthalmological studies. It ensures instant precision spectral reproducibility, whereas only sequential normalization of the light intensity is available with integrated photodiode. The instrument consists of a sensitive CCD camera that enables high definition imaging. It is available in a XYZ manual positioning system and chin rest configuration. The company’s patented Bragg grating filtering technology generates illumination, while supercontinuum source enables the selection of rapid and accurate wavelength less than 1 nm.
IRIS, with their specific spectral signatures ensures effectual non-invasive localization of structures and biomolecules in the retina. Photon etc. has achieved successful partnership with Glaucoma and Retina Research Group at the University of Waterloo/University Health Network and as a result formulates a technique to investigate retinal blood vessels and its blood oxygen saturation. Development of this novel system creates awareness about eye disorders and with spectral signatures prevents any biomolecule or structure from being damaged.